EFPIA prepares list of actions that need to be taken in event of no-deal Brexit

By PharmaCompass

2019-01-17

Impressions: 332 Article

This week’s big news came from the UK, where Prime Minister Theresa May’s Brexit deal was rejected by 230 votes — the largest defeat for a sitting government in history.

With the UK now bracing the possibility of a no-deal Brexit, the European Federation of Pharmaceutical Industries and Association (EFPIA) said in a statement: “With the prospect of the UK leaving the European Union in a disorderly manner on 30 March 2019 without a deal, there are very real, tangible and immediate threats to patient safety and public health in both the UK and across Europe.”

The EFPIA has urged negotiators to agree on a series of actions that need to be taken to protect patients, such as the introduction of measures that will continue to recognize UK-based testing at least until it can be transferred to the EU. “It is critical that, in the event of a ‘no deal’, the EU introduces a measure that will continue to recognize UK-based testing at least until it can be transferred to the EU,” the EFPIA said.

The body has also recommended measures to enable the continued UK participation in key data sharing platforms that protect public health and medicines safety in Europe.

A “no deal” scenario presents a clear threat of disruption to the supply of medicines throughout the EU. Every month, 82 million packs of medicines move between the UK and the EU. Therefore, the EFPIA has asked for discussions between relevant authorities and the pharmaceutical sector to co-ordinate contingency plans such as putting fast track lanes or priority routes for medicines into ports and airports.

“Medicines and clinical trial materials should be temporarily exempted from any new customs and borders checks,” the body said.

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass